As mentioned in our previous coverage DMT seems to be a psychedelic medicine rising star, with more and more firms focusing their work around this potent compound.
In recent news that went very much under the radar, a new player seems to be making its way into the psychedelic medicine space – and potentially onto the NASDAQ – with DMT.
GH Research is an Ireland-based company founded in 2018. Their website describes them as a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders.
Their initial focus is on developing novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.
DMT portfolio in development and clinical trials underway
Their main products in development are GH001, a proprietary inhalable 5-MeO-DMT drug candidate, and GH002, a proprietary injectable 5-MeO-DMT product candidate. You can read about their pipeline here.
GH Research is also somewhat advanced in its clinical trial process, having completed a Phase 1 volunteer clinical trial where GH001 was observed to be well tolerated. GH001 is currently being investigated in the Phase 2 part of an ongoing Phase 1/2 clinical trial in patients with depression.
The company believes that “its inhalable drug candidate has the potential to induce ultra-rapid remissions in certain patients, driven by the ultra-rapid onset of psychoactive effects and an intense and short-lived initial psychoactive experience.”
Funding and SEC filing for NASDAQ listing
As if a new company suddenly appearing on the scene with a Phase 2 DMT for depression trial wasn’t enough, it seems they’ve also been advancing their financial position quite aggressively.
In April, GH Research announced the closing of a $125 million Series B financing. That’s an impressive number for a still private firm. The funding was co-led by names like RA Capital and RTW Investments, and other U.S.-based biopharmaceutical investment firms.
And in the most recent news, GH apparently just filed with the SEC for a NASDAQ listing intended to raise up to $100 million. This report says that GH plans to list on the NASDAQ under the symbol GHRS and that they filed confidentially with the SEC on April 20th.
Please note that this last part is still a tad unconfirmed and short on official press releases. We’re working on getting more solid confirmations and will update you accordingly. But for now, it seems there might be a new major player in town. Stay tuned.
As mentioned in our previous coverage DMT seems to be a psychedelic medicine rising star, with more and more firms focusing their work around this potent compound.
In recent news that went very much under the radar, a new player seems to be making its way into the psychedelic medicine space – and potentially onto the NASDAQ – with DMT.
GH Research is an Ireland-based company founded in 2018. Their website describes them as a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders.
Their initial focus is on developing novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.
DMT portfolio in development and clinical trials underway
Their main products in development are GH001, a proprietary inhalable 5-MeO-DMT drug candidate, and GH002, a proprietary injectable 5-MeO-DMT product candidate. You can read about their pipeline here.
GH Research is also somewhat advanced in its clinical trial process, having completed a Phase 1 volunteer clinical trial where GH001 was observed to be well tolerated. GH001 is currently being investigated in the Phase 2 part of an ongoing Phase 1/2 clinical trial in patients with depression.
The company believes that “its inhalable drug candidate has the potential to induce ultra-rapid remissions in certain patients, driven by the ultra-rapid onset of psychoactive effects and an intense and short-lived initial psychoactive experience.”
Funding and SEC filing for NASDAQ listing
As if a new company suddenly appearing on the scene with a Phase 2 DMT for depression trial wasn’t enough, it seems they’ve also been advancing their financial position quite aggressively.
In April, GH Research announced the closing of a $125 million Series B financing. That’s an impressive number for a still private firm. The funding was co-led by names like RA Capital and RTW Investments, and other U.S.-based biopharmaceutical investment firms.
And in the most recent news, GH apparently just filed with the SEC for a NASDAQ listing intended to raise up to $100 million. This report says that GH plans to list on the NASDAQ under the symbol GHRS and that they filed confidentially with the SEC on April 20th.
Please note that this last part is still a tad unconfirmed and short on official press releases. We’re working on getting more solid confirmations and will update you accordingly. But for now, it seems there might be a new major player in town. Stay tuned.